Teva EVP Global R&D Dr. Hafrun Fridriksdottir to depart, search underway

TEVA PHARMACEUTICAL INDUSTRIES LTD

Dr. Hafrun Fridriksdottir, EVP Global R&D, is leaving Teva.
She will remain in role until June 20, 2022 to assist transition.
Teva has initiated a search for the next head of Global R&D.
No successor has been named as of the filing date.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Hafrun Fridriksdottir

Executive Vice President, Global R&D

TEVA · TEVA PHARMACEUTICAL INDUSTRIES LTD

Effective: 2022-06-20
Filed: February 24, 2022, 6:59 PM ET

Dr. Hafrun Fridriksdottir, Executive Vice President, Global R&D, will be leaving Teva Pharmaceutical Industries Ltd.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hafrun Fridriksdottir departed as Executive Vice President, Global R&D at TEVA PHARMACEUTICAL INDUSTRIES LTD.

Action: leaving
Role: Executive Vice President, Global R&D

Exact text from the filing

Dr. Hafrun Fridriksdottir, Executive Vice President, Global R&D, will be leaving Teva Pharmaceutical Industries Ltd.

View on SEC.gov

TEVA PHARMACEUTICAL INDUSTRIES LTD filing history →

Source: SEC EDGAR

accession 0001193125-22-052050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.